Vascular Detransformation for Cancer Therapy

Trends Cancer. 2019 Aug;5(8):460-463. doi: 10.1016/j.trecan.2019.05.007. Epub 2019 Jun 14.

Abstract

Angiogenesis is a hallmark of cancer. However, current antivascular therapies that primarily target angiogenic factors have faced difficulties and failures in treating most cancers. It is proposed that endothelial transformation acts as an alternative driver of excessive and abnormal vascularity that fuels cancer progression and immunosuppression, and also induces resistance to therapy. Thus, vascular detransformation may serve as a promising therapeutic strategy against cancer.

Keywords: angiogenesis; antivascular therapy; cancer; endothelial transformation; endothelial–mesenchymal transition.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use*
  • Drug Resistance, Neoplasm
  • Endothelial Cells / drug effects
  • Endothelial Cells / pathology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology*
  • Epithelial-Mesenchymal Transition / drug effects*
  • Humans
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / pathology

Substances

  • Angiogenesis Inhibitors